Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30679
Title: The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review.
Austin Authors: Kiamanesh, Zahra;Ayati, Narjess ;Sadeghi, Ramin;Hawkes, Eliza A ;Lee, Sze Ting ;Scott, Andrew M 
Affiliation: School of Public Health & Preventative Medicine, Monash University, Melbourne, Australia..
Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran..
Department of Nuclear Medicine, Ultrasound & PET, Sydney Westmead Hospital, Sydney, NSW, Australia..
School of Cancer Medicine, La Trobe University, Victoria, Australia..
Department of Medicine, University of Melbourne, Victoria, Australia..
Molecular Imaging and Therapy
Medical Oncology
Clinical Haematology
Olivia Newton-John Cancer Research Institute
Issue Date: 6-Aug-2022
Date: 2022
Publication information: European Journal of Nuclear Medicine and Molecular Imaging 2022
Abstract: Treatment strategies of lymphoid malignancies have been revolutionized by immunotherapy. Because of the inherent property of Hodgkin lymphoma and some subtypes of non-Hodgkin lymphoma as a highly FDG-avid tumor, functional 18F-FDG PET/CT imaging is already embedded in their routine care. Nevertheless, the question is whether it is still valuable in the context of these tumors being treated with immunotherapy. Herein, we will review the value of 18F-FDG PET/CT imaging lymphoid tumors treated with immunotherapy regimens. A comprehensive literature search of the PubMed database was conducted on the value of the 18F-FDG PET/CT for immunotherapy response monitoring of patients with malignant lymphoma. The articles were considered eligible if they met all of the following inclusion criteria: (a) clinical studies on patients with different types of malignant lymphoma, (b) treatment with anti-CD20 antibodies, immune checkpoint inhibitors or immune cell therapies, (c) and incorporated PET/CT with 18F-FDG as the PET tracer. From the initial 1488 papers identified, 91 were ultimately included in our study. In anti-CD20 therapy, the highest pooled hazard ratios (HRs) of baseline, early, and late response monitoring parameters for progression-free survival (PFS) belong to metabolic tumor volume (MTV) (3.19 (95%CI: 2.36-4.30)), maximum standardized uptake value (SUVmax) (3.25 (95%CI: 2.08-5.08)), and Deauville score (DS) (3.73 (95%CI: 2.50-5.56)), respectively. These measurements for overall survival (OS) were MTV (4.39 (95%CI: 2.71-7.08)), DS (3.23 (95%CI: 1.87-5.58)), and DS (3.64 (95%CI: 1.40-9.43)), respectively. Early and late 18F-FDG PET/CT response assessment in immune checkpoint inhibitors (ICI) and immune cell therapy might be an effective tool for prediction of clinical outcome. For anti-CD20 therapy of lymphoma, the MTV as a baseline 18F-FDG PET/CT-derived parameter has the highest HRs for PFS and OS. The DS as visual criteria in early and late response assessment has higher HRs for PFS and OS compared to the international harmonization project (IHP) visual criteria in anti-CD20 therapy. Early changes in 18F-FDG PET parameters may be predictive of response to ICIs and cell therapy in lymphoma patients.
URI: https://ahro.austin.org.au/austinjspui/handle/1/30679
DOI: 10.1007/s00259-022-05918-2
ORCID: http://orcid.org/0000-0002-6656-295X
http://orcid.org/0000-0001-8482-4119
http://orcid.org/0000-0002-0376-2559
http://orcid.org/0000-0001-8641-456X
Journal: European journal of nuclear medicine and molecular imaging
PubMed URL: 35932329
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/35932329/
Type: Journal Article
Subjects: 18F-FDG PET/CT
Anti-CD20 antibodies
Immune checkpoint inhibitors
Immunotherapy
Malignant lymphoma
Appears in Collections:Journal articles

Show full item record

Page view(s)

32
checked on May 18, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.